Medindia LOGIN REGISTER
Medindia
Advertisement

EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference

Wednesday, February 27, 2008 General News
Advertisement
ROCKVILLE, Md., Feb. 26 EntreMed, Inc.(Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeuticsfor the treatment of cancer and inflammatory diseases, today announced thatJames S. Burns, President and Chief Executive Officer, will present aCorporate overview at the Jesup & Lamont Emerging Growth Stock Conference,which will be held at the Disney Contemporary Resort in Orlando, Florida onThursday, February 28, 2008. Mr. Burns is scheduled to present at 1:35 p.m.(local time).
Advertisement

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO)

Mr. Burns' live presentation will not be web cast, but will be availablethrough the Company's web site at www.entremed.com.
Advertisement

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developingtherapeutic candidates primarily for the treatment of cancer and inflammation.MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is anoral cell-cycle regulator with activity against the mTOR pathway. Panzem(R)(2-methoxyestradiol) NCD is also in multiple Phase 2 studies in oncologypatients. Additionally, ENMD-1198, a novel anticancer drug, is in Phase 1studies in advanced cancers. The Company has approved IND applications forPanzem(R) in rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora-angiogenesis inhibitor, for cancer. EntreMed's goal is to develop andcommercialize new compounds based on the Company's expertise in angiogenesis,cell-cycle regulation and inflammation - processes vital to the treatment ofcancer and other diseases, such as rheumatoid arthritis. Additionalinformation about EntreMed is available on the Company's web site atwww.entremed.com and in various filings with the Securities and ExchangeCommission.CONTACT: Ginny Dunn Associate Director Corporate Communications & Investor Relations EntreMed, Inc. 240-864-2643

SOURCE EntreMed, Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close